Abstracts Archive - Page 2145 of 2425 - ACR Meeting Abstracts

Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Dandan Wang¹, Lin Lu², Xuebing Feng³, Xia Li² and Lingyun Sun³, ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…
Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
David Wofsy¹, David A. Isenberg², Daiana Licu³, Yong Li⁴, Claudia Pena Rossi³ and Caroline Gordon⁵, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Merck Serono S.A., Geneva, Switzerland, ⁴EMD Serono, Rockland, MA, ⁵Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…
Abstract Number: 1592 • 2013 ACR/ARHP Annual Meeting
“Lupus Headache”: Results From a Prospective, International, Inception Cohort Study
John G. Hanly¹, Murray B. Urowitz², Aidan o'Keeffe³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Ann E. Clarke⁸, Sasha Bernatsky⁹, Daniel J. Wallace¹⁰, E.M. Ginzler¹¹, David A. Isenberg¹², Anisur Rahman¹³, Joan T. Merrill¹⁴, Michelle A. Petri¹⁵, Paul R. Fortin¹⁶, D. D. Gladman¹⁷, Barri J. Fessler¹⁸, Graciela S. Alarcon¹⁹, Ian N. Bruce²⁰, Mary Anne Dooley²¹, Kristjan Steinsson²², Munther A. Khamashta²³, Rosalind Ramsey-Goldman²⁴, Susan Manzi²⁵, Gunnar K. Sturfelt²⁶, Ola Nived²⁷, Asad A. Zoma²⁸, R. F. van Vollenhoven²⁹, Manuel Ramos-Casals³⁰, Cynthia Aranow³¹, Meggan Mackay³², Guillermo Ruiz-Irastorza³³, Kenneth C. Kalunian³⁴, S. Sam Lim³⁵, Murat Inanc³⁶, Diane L. Kamen³⁷, Christine Peschken³⁸, Søren Jacobsen³⁹, Chris Theriault⁴⁰, Kara Thompson⁴⁰ and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁹Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ¹⁷Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁸Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁰Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²²Rheumatology, Landspital Univ Hospital, Reykjavik, Iceland, ²³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁵Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁶Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁷Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ²⁸Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²⁹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³⁰Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ³¹The Feinstein Institute, Manhasset, NY, ³²Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ³³Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁴UCSD School of Medicine, La Jolla, CA, ³⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³⁶Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Department of Medicine, Medical University of South Carolina, Charleston, SC, ³⁸Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: “Lupus headache” is controversial and is included in validated measures of global SLE disease activity. We examined the frequency and characteristics of “lupus headache”…
Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Graciela Gómez¹, Judith Sarano², Maria de los Angeles Gargiulo¹, María Victoria Collado², Lorena Suarez¹, Daniel Fadel³, Alexandra Panopulos⁴ and Marina Khoury⁵, ¹Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ²Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³Psychiatric, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁴Neurology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁵Research and Teaching, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…
Abstract Number: 1595 • 2013 ACR/ARHP Annual Meeting
Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus
Jamal Mikdashi¹, Tricia Ting² and Allan Krumholz³, ¹Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Neurology, University of Maryland. School of Medicine, Baltimore, MD, ³Neurology, University fo Maryland school of Medicine, Baltimore, MD
Background/Purpose: Predictors of seizures and epilepsy in systemic lupus erythematosus (SLE) patients are well described but descriptions of status epilepticus (SE) have thus far been…
Abstract Number: 1598 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, a Non-Inflammatory Neuropsychiatric Syndrome In Systemic Lypus Erythematosus
Juanita Romero-Díaz¹, Alí Duarte-García², Sandra Juarez-Arellano³, Alba Cicero-Casarrubias¹, Hilda Fragoso-Loyo⁴, Luis Llorente⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁵Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) affects 15 – 60% of SLE patients; nevertheless, its pathogenesis and predisposing factors are unknown. Objective: To identify factors associated with CD…
Abstract Number: 1599 • 2013 ACR/ARHP Annual Meeting
High Proportion Of Intrathecal Ro52 SSA Antibodies In Neuropsychiatric Lupus Patients – Relations To Neuropsychiatric Manifestations
Johanna Estelius¹, Liisa Hopia², Vijole Dzikaite-Ottosson³, Magnus LA. Andersson⁴, Elisabet Svenungsson⁵ and Jon Lampa⁶, ¹Department of Medicine, Rheumatology Unit, Center for Molecular medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ⁴Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Neuropsychiatric (NP) manifestations in Systemic Lupus Erythematosus (SLE) are often associated with significant impact on quality of life and work capability. The underlying mechanisms…
Abstract Number: 1600 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Yoshiyuki Arinuma¹, Hirotoshi Kikuchi², Eisuke Ogawa¹, Tatsuhiko Wada¹, Tatsuo Nagai³, Sumiaki Tanaka¹ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the…
Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting
The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Taku Yoshio¹, Hiroshi Okamoto², Kazuhiro Kurasawa³, Yoshiaki Dei⁴, Shunsei Hirohata⁵ and Seiji Minota⁶, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ²Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…
Abstract Number: 1602 • 2013 ACR/ARHP Annual Meeting
Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Hilda Fragoso-Loyo¹, Alí Duarte-García², Sandra Juárez-Arellano³, Alba Cicero-Casarrubias⁴, Juanita Romero-Díaz⁵, Luis LLorente-Peters¹ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: The nature and pathogenesis and cognitive dysfunction (CD) in patients with SLE is unkown.To determine the presence and levels of autoantibodies, cytokines and chemokines…
Abstract Number: 1561 • 2013 ACR/ARHP Annual Meeting
Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Ronald F. van Vollenhoven¹, Marta Mosca², George Bertsias³, Annegret Kuhn⁴, Kirsten Lerstrøm⁵, Josef S. Smolen⁶, David A. Isenberg⁷, Matthias Schneider⁸ and the T2T/SLE Working Party⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²I, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, ³Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁴University of Münster, Münster, Germany, ⁵Lupus Europe, Farum, Denmark, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁸Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁹the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and…
Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Laurent Arnaud¹, Alexis Mathian², Hervé Devilliers³, Du Boutin-LE Thi Huong⁴, Ahlem Chaib⁴, Fleur Cohen-Aubart⁴, Julien Haroche¹, Miguel Hié⁴, Makoto Miyara⁴ and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…
Abstract Number: 1565 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine
Christopher J. Lessard^1,2, Indra Adrianto³, Joel M. Guthridge⁴, John A. Ice³, Graham B. Wiley³, Stuart B. Glenn³, Judith A. James^1,2, Joan T. Merrill¹, Patrick M. Gaffney¹, Courtney G. Montgomery³, Kathy L. Sivils^1,5 and Eliza Chakravarty³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE patients have increased risk of Herpes Zoster (HZ). A live-attenuated vaccine is available for healthy persons > 50 years old, but its safety…
Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Eric F. Morand¹, Kate Franklyn¹, Chak S. Lau², Sandra V. Navarra³, Worawit Louthrenoo⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Singgih Wahono⁷, Shun-Le Chen⁸, Jinou Ou⁹, Alberta Y. Hoi¹ and Mandana Nikpour¹⁰, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³University of Santo Tomas Hospital, Manila, Philippines, ⁴Dept of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Bandung, Indonesia, ⁷Universitas Brawijaya, Malang, Indonesia, ⁸Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁹3rd Hospital of Sun Yat-san University, Guang Zhou, China, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].